Vesicle Therapeutics Inc.
Longmont, CO Vesicle Therapeutics Inc.
- UEI
- KALZFKXVQTA6
- CAGE
- 8UT94
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 7007 Johnson Cir, Longmont, CO 80503, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeting STAT3 with novel thiomorpholino antisense oligonucleotides for cancer therapy - project summary vesicle… | National Cancer Institute | $400,000 | |
| Neurotropic gectosomes as a CNS gene delivery system for ad/adrd therapy development | National Institute on Drug Abuse | $475,152 | |
| Targeting GPR146 for the treatment of homozygous familial hypercholesterolemia - project summary vesicle therapeutics… | National Heart Lung and Blood Institute | $855,690 | |
| Development of a gectosome therapy for cardiovascular diseases - project summary vesicle therapeutics INC aims to… | National Heart Lung and Blood Institute | $633,646 |
About Vesicle Therapeutics Inc.
Vesicle Therapeutics Inc. is a small business biotechnology company specializing in innovative drug delivery technologies, with a focus on developing advanced therapeutic solutions using proprietary gectosome nanoparticle platforms. The company leverages its unique technology to enable targeted and efficient delivery of therapeutic agents across various medical domains, including neurological disorders, cancer treatment, and cardiovascular diseases. Registered in SAM.gov since January 2021, Vesicle Therapeutics Inc. operates as a for-profit corporate entity with expertise in developing advanced gene delivery and targeted therapy platforms.
The company has secured a federal contract from the National Institute on Aging with a value of $475,152, specifically focused on developing neurotropic gectosomes as a central nervous system gene delivery system for Alzheimer's disease and related dementias therapy development. This contract was set aside for total small business participation, highlighting the company's specialized capabilities in neurological therapeutic research. The contract, which runs from September 2022 to September 2024, demonstrates Vesicle Therapeutics Inc.'s commitment to advancing innovative treatment approaches for complex neurological conditions through its proprietary delivery technology.
Vesicle Therapeutics Inc. has received multiple federal grants from agencies like the National Cancer Institute and the National Heart, Lung, and Blood Institute, supporting research in diverse therapeutic areas. The company's grant portfolio includes a $400,000 project grant from the National Cancer Institute to develop an antisense oligonucleotide therapy targeting head and neck squamous cell carcinoma, and two grants from the National Heart, Lung, and Blood Institute focusing on developing therapies for homozygous familial hypercholesterolemia. These grants, ranging from $400,000 to support cancer research to projects exploring targeted gene silencing for cardiovascular diseases, showcase the company's versatility in applying its gectosome delivery technology across multiple medical domains, with a strong emphasis on developing innovative, targeted therapeutic solutions.
Quick answers
What is Vesicle Therapeutics Inc.'s UEI?
Vesicle Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is KALZFKXVQTA6.
What is Vesicle Therapeutics Inc.'s CAGE code?
Vesicle Therapeutics Inc.'s CAGE code is 8UT94.
What is Vesicle Therapeutics Inc.'s primary NAICS code?
Vesicle Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Vesicle Therapeutics Inc. located?
Vesicle Therapeutics Inc.'s physical address in SAM.gov is 7007 Johnson Cir, Longmont, CO 80503, USA.
Is Vesicle Therapeutics Inc. registered in SAM.gov?
Yes. Vesicle Therapeutics Inc.'s SAM.gov registration is active through June 2, 2027.
What is Vesicle Therapeutics Inc.'s most recent federal award?
Vesicle Therapeutics Inc.'s most recent federal grant award is Targeting STAT3 with novel thiomorpholino antisense oligonucleotides for cancer therapy - project summary vesicle… (R41CA287794), from National Cancer Institute, on September 16, 2025.
On GovTribe
See Vesicle Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors